Expert Opinion on Drug Safety : Impact Factor & More
eISSN: 1744-764XpISSN: 1474-0338
Share this on:
Aims and Scope of Expert Opinion on Drug Safety
Expert Opinion on Drug Safety is a monthly peer-reviewed medical journal publishing review articles on all aspects of pharmacovigilance and original papers on the clinical implications of drug treatment safety issues. It was established in 2002 and is published by Informa. The editor-in-chief is Roger McIntyre (University of Toronto). Less
Key Metrics
CiteScore 
6.1
Eigenfactor
0.005 - 0.01
H-Index
81
Impact Factor
< 5
SJR
Q2Pharmacology (medical)
SNIP
1.17
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Expert Opinion on Drug Safety
Expert Opinion on Drug Safety Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Drug Safety ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Expert Opinion on Drug Safety
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations
- 3 Oct 2026
- Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
- 3 Oct 2026
- Expert Opinion on Drug Safety
Bridging evidence gaps in dravet syndrome: real-world safety insights from under-reported antiseizure therapies
- 3 Oct 2026
- Expert Opinion on Drug Safety
Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?
- 3 Oct 2026
- Expert Opinion on Drug Safety
Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits
- 2 Sep 2026
- Expert Opinion on Drug Safety
Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies
- 6 May 2026
- Expert Opinion on Drug Safety
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations
- 3 Oct 2026
- Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
- 3 Oct 2026
- Expert Opinion on Drug Safety
Bridging evidence gaps in dravet syndrome: real-world safety insights from under-reported antiseizure therapies
- 3 Oct 2026
- Expert Opinion on Drug Safety
Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?
- 3 Oct 2026
- Expert Opinion on Drug Safety
Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits
- 2 Sep 2026
- Expert Opinion on Drug Safety
Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies
- 6 May 2026
- Expert Opinion on Drug Safety
FAQs on Expert Opinion on Drug Safety
How long has Expert Opinion on Drug Safety been actively publishing? 
What is the publishing frequency of Expert Opinion on Drug Safety?
How many articles did Expert Opinion on Drug Safety publish last year?
What is the eISSN & pISSN for Expert Opinion on Drug Safety?
What is Citescore for Expert Opinion on Drug Safety?
What is the H Index for Expert Opinion on Drug Safety ?
What is SNIP score for Expert Opinion on Drug Safety?
What is the SJR for Expert Opinion on Drug Safety?
Who is the publisher of Expert Opinion on Drug Safety?
